Advances in Treatment of Previously Treated Ph+ Chronic Myeloid Leukemia

Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.

Shared insight on chromosomal abnormalities and genetic alterations that influence the disease course and management of CML.

Key opinion leader perspectives on assessing a patient’s response to therapy for chronic myeloid leukemia.

Daniel DeAngelo, MD, PhD, highlights the role that tyrosine kinase inhibitors play in the CML treatment paradigm.

Considerations for selecting optimal second-line therapy for chronic myeloid leukemia when a patient progresses.

A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.

Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.

Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.

Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.

A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.

An overview of the general toxicities patients may experience while undergoing therapy for chronic myeloid leukemia.

Daniel DeAngelo, MD, PhD, provides his perspective on improving CML care through dose adjustment or treatment discontinuation.

Moshe Talpaz, MD, discusses best practices in monitoring patients with CML and applying multidisciplinary care.

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.